数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

   KYTX
-- -- --

今开：-- 昨收：-- 最高：-- 最低：--
成交量：--万手 市盈率：-- 总市值($)：-- 换手率：--
加入自选股

首页概览 公司概况 财务分析 高管介绍 股本结构 公司新闻

董事介绍

注：董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
イアンクラーク 男 Director 65 26.00万美元 34.61 2026-04-13
Christi Shaw 女 Director and Executive Chairperson 59 31.99万美元 7.38 2026-04-13
Andrew Miller 男 Director 44 未披露 0.24 2026-04-13
Beth Seidenberg 女 Director 69 24.25万美元 467.65 2026-04-13
Warner Biddle 男 Chief Executive Officer and Director 59 181.50万美元 111.10 2026-04-13
Mert Aktar 男 Director 47 23.25万美元 4.39 2026-04-13
Sravan Emany 男 Director 48 未披露 0.24 2026-04-13
Fred E. Cohen 男 Director 69 23.75万美元 454.32 2026-04-13

高管介绍

注：高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Christi Shaw 女 Director and Executive Chairperson 59 31.99万美元 7.38 2026-04-13
Marc Grasso 男 Chief Financial Officer 54 166.35万美元 未持股 2026-04-13
Warner Biddle 男 Chief Executive Officer and Director 59 181.50万美元 111.10 2026-04-13
Naji H. Gehchan 男 Chief Medical and Development Officer 44 208.52万美元 13.28 2026-04-13
Mayo Pujols 男 Chief Technology Officer 57 未披露 未持股 2026-04-13

董事简历

中英对照 |  中文 |  英文
イアンクラーク

Ian Clark，自2017年1月起担任董事会成员，为首席独立董事。克拉克先生最近担任首席执行官，领导执行委员会，并在2010年1月至2016年12月期间担任生物技术公司Genentech Inc.的董事会成员。他总共在基因泰克服务了14年，其中12年是基因泰克执行委员会成员，最初担任商业运营执行副总裁。在此之前，他曾担任高级副总裁兼生物肿瘤总经理。在此之前，克拉克先生在诺华、赛诺菲、Ivax和Searle担任了20年的职责不断增加的职位，曾在英国、加拿大、东欧和法国工作。Clark目前在Takeda Pharmaceutical Company Limited、Olema Pharmaceuticals, Inc.、Kyverna Therapeutics Inc、Corvus制药，Inc.和BioMarin Pharmaceutical Inc.的董事会任职。2026年6月，Clark先生将结束在Takeda Pharmaceutical Company Limited董事会的服务，并已向公司董事会传达了他进一步减少2026年董事会服务的意图。他此前曾在Shire Pharmaceuticals、Kite Pharma、GYROscope、Forty Seven、Agios、Dendreon、Vernalis、AVROBIO，Inc.和GoodRX Holdings，Inc.的董事会任职。Clark是KKR的顾问，此前曾担任Lazard、黑石生命科学、Perella Weinberg Partners的顾问。他曾担任生物技术行业组织（BIO）的董事会成员，并担任美联储第12届地区经济顾问委员会（EAC）成员。他还曾在格拉德斯通研究所的BioFulcrum董事会任职，并担任南安普顿大学生命科学研究所外部顾问委员会主席。克拉克先生获得了南安普顿大学的理学学士学位和生物科学荣誉博士学位。


Ian Clark,has served as a member of Board since January 2017 and is lead independent director. Mr. Clark most recently served as CEO, led the Executive Committee, and was a member of the Board of Directors of Genentech Inc., a biotechnology company, from January 2010 to December 2016. In total he served for 14 years at Genentech of which 12 were on the Genentech Executive Committee, initially as Executive Vice President of Commercial Operations. Before that, he served as Senior Vice President and General Manager of BioOncology. Prior to this, Mr. Clark spent 20 years in positions of increasing responsibility at Novartis, Sanofi, Ivax, and Searle, working in the United Kingdom, Canada, Eastern Europe and France.Mr. Clark currently serves on the Board of Directors of Takeda Pharmaceutical Company Limited, Olema Pharmaceuticals, Inc., Kyverna Therapeutics Inc, Corvus Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. In June 2026, Mr. Clark will end his service on the Board of Directors of Takeda Pharmaceutical Company Limited, and has communicated to the Company's Board his intent to further reduce his board service in 2026. He previously served on the Board of Directors of Shire Pharmaceuticals, Kite Pharma, Gyroscope, Forty Seven, Agios, Dendreon, Vernalis, AVROBIO, Inc. and GoodRx Holdings, Inc.Mr. Clark is an advisor to KKR and was previously an advisor at Lazard, Blackstone Life Sciences, and Perella Weinberg Partners. He served on the Board of the Biotechnology Industry Organization (BIO) and as a member of the 12th District Economic Advisory Council (EAC) of the Federal Reserve. He also served on the BioFulcrum Board of the Gladstone Institute and as Chair of the External Advisory Board to Southampton University's Institute for Life Sciences. Mr. Clark received a B.Sc. and an honorary doctorate in biological sciences from Southampton University.
Ian Clark，自2017年1月起担任董事会成员，为首席独立董事。克拉克先生最近担任首席执行官，领导执行委员会，并在2010年1月至2016年12月期间担任生物技术公司Genentech Inc.的董事会成员。他总共在基因泰克服务了14年，其中12年是基因泰克执行委员会成员，最初担任商业运营执行副总裁。在此之前，他曾担任高级副总裁兼生物肿瘤总经理。在此之前，克拉克先生在诺华、赛诺菲、Ivax和Searle担任了20年的职责不断增加的职位，曾在英国、加拿大、东欧和法国工作。Clark目前在Takeda Pharmaceutical Company Limited、Olema Pharmaceuticals, Inc.、Kyverna Therapeutics Inc、Corvus制药，Inc.和BioMarin Pharmaceutical Inc.的董事会任职。2026年6月，Clark先生将结束在Takeda Pharmaceutical Company Limited董事会的服务，并已向公司董事会传达了他进一步减少2026年董事会服务的意图。他此前曾在Shire Pharmaceuticals、Kite Pharma、GYROscope、Forty Seven、Agios、Dendreon、Vernalis、AVROBIO，Inc.和GoodRX Holdings，Inc.的董事会任职。Clark是KKR的顾问，此前曾担任Lazard、黑石生命科学、Perella Weinberg Partners的顾问。他曾担任生物技术行业组织（BIO）的董事会成员，并担任美联储第12届地区经济顾问委员会（EAC）成员。他还曾在格拉德斯通研究所的BioFulcrum董事会任职，并担任南安普顿大学生命科学研究所外部顾问委员会主席。克拉克先生获得了南安普顿大学的理学学士学位和生物科学荣誉博士学位。
Ian Clark,has served as a member of Board since January 2017 and is lead independent director. Mr. Clark most recently served as CEO, led the Executive Committee, and was a member of the Board of Directors of Genentech Inc., a biotechnology company, from January 2010 to December 2016. In total he served for 14 years at Genentech of which 12 were on the Genentech Executive Committee, initially as Executive Vice President of Commercial Operations. Before that, he served as Senior Vice President and General Manager of BioOncology. Prior to this, Mr. Clark spent 20 years in positions of increasing responsibility at Novartis, Sanofi, Ivax, and Searle, working in the United Kingdom, Canada, Eastern Europe and France.Mr. Clark currently serves on the Board of Directors of Takeda Pharmaceutical Company Limited, Olema Pharmaceuticals, Inc., Kyverna Therapeutics Inc, Corvus Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. In June 2026, Mr. Clark will end his service on the Board of Directors of Takeda Pharmaceutical Company Limited, and has communicated to the Company's Board his intent to further reduce his board service in 2026. He previously served on the Board of Directors of Shire Pharmaceuticals, Kite Pharma, Gyroscope, Forty Seven, Agios, Dendreon, Vernalis, AVROBIO, Inc. and GoodRx Holdings, Inc.Mr. Clark is an advisor to KKR and was previously an advisor at Lazard, Blackstone Life Sciences, and Perella Weinberg Partners. He served on the Board of the Biotechnology Industry Organization (BIO) and as a member of the 12th District Economic Advisory Council (EAC) of the Federal Reserve. He also served on the BioFulcrum Board of the Gladstone Institute and as Chair of the External Advisory Board to Southampton University's Institute for Life Sciences. Mr. Clark received a B.Sc. and an honorary doctorate in biological sciences from Southampton University.
Christi Shaw

Christi Shaw是Eli Lilly公司的高级副总裁，Eli Lilly公司是一家全球医疗保健公司，也是礼来生物医药公司的总裁，礼来公司是Eli Lilly公司的业务部门，其中包括自2017年4月以来一直担任的神经科学和免疫学。2014年至2016年，Shaw女士担任全球医疗保健公司Novartis Pharmaceutical Corporation的美国区域负责人和总裁，并于2010年至2014年担任诺华公司的北美地区负责人。2010年之前，Shaw女士在强生公司担任多个领导职务。Shaw女士还担任生物技术创新组织的执行董事会成员，并且是More Moments More Memories Foundation的联合创始人。Shaw女士拥有爱荷华州立大学市场营销学士学位和威斯康星大学工商管理硕士学位。


Christi Shaw has served as a member of Kyverna Therapeutics, Inc.'s Board since September 2024 and as Executive Chairperson of Kyverna Therapeutics, Inc.'s Board since January 12, 2026. Ms. Shaw is a seasoned healthcare executive with over 30 years of experience in the biopharmaceutical industry. Most recently, she served as Chief Executive Officer of Kite Pharma, Inc., a Gilead company specializing in the development of cancer immunotherapies, from August 2019 to March 2023. Ms. Shaw has served on the board of directors of Beam Therapeutics Inc. (Nasdaq: BEAM) since December 2023 and on the board of directors for ReAlta Life Sciences, Inc. from January 2024 until September 2025. Ms. Shaw also served as a director of Avantor, Inc. (NYSE: AVTR) from November 2018 through May 2024. From April 2017 to August 2019, she served as Senior Vice President of Eli Lilly & Co. (NYSE: LLY), a global healthcare company, and President of Lilly Bio Medicines, the business within Eli Lilly Company that comprised its neuroscience and immunology divisions. From 2014 to 2016, Ms. Shaw served as U.S. country head and President of Novartis Pharmaceutical Corporation, a global healthcare company, and from 2010 to 2014, as North American region head of Novartis Oncology. Prior to 2010, Ms. Shaw held several leadership positions at Johnson & Johnson, Inc. (NYSE: JNJ). Previously, she served as an executive committee member of the Biotechnology Innovation Organization. Ms. Shaw is also an advisor for Family Reach's Clinical Trial Access Program, which she co founded with her sister (More Moments More Memories) to assist people with cancer access clinical trials. Ms. Shaw holds a B.B.A. in Marketing from Iowa State University and an M.B.A. from the University of Wisconsin.
Christi Shaw是Eli Lilly公司的高级副总裁，Eli Lilly公司是一家全球医疗保健公司，也是礼来生物医药公司的总裁，礼来公司是Eli Lilly公司的业务部门，其中包括自2017年4月以来一直担任的神经科学和免疫学。2014年至2016年，Shaw女士担任全球医疗保健公司Novartis Pharmaceutical Corporation的美国区域负责人和总裁，并于2010年至2014年担任诺华公司的北美地区负责人。2010年之前，Shaw女士在强生公司担任多个领导职务。Shaw女士还担任生物技术创新组织的执行董事会成员，并且是More Moments More Memories Foundation的联合创始人。Shaw女士拥有爱荷华州立大学市场营销学士学位和威斯康星大学工商管理硕士学位。
Christi Shaw has served as a member of Kyverna Therapeutics, Inc.'s Board since September 2024 and as Executive Chairperson of Kyverna Therapeutics, Inc.'s Board since January 12, 2026. Ms. Shaw is a seasoned healthcare executive with over 30 years of experience in the biopharmaceutical industry. Most recently, she served as Chief Executive Officer of Kite Pharma, Inc., a Gilead company specializing in the development of cancer immunotherapies, from August 2019 to March 2023. Ms. Shaw has served on the board of directors of Beam Therapeutics Inc. (Nasdaq: BEAM) since December 2023 and on the board of directors for ReAlta Life Sciences, Inc. from January 2024 until September 2025. Ms. Shaw also served as a director of Avantor, Inc. (NYSE: AVTR) from November 2018 through May 2024. From April 2017 to August 2019, she served as Senior Vice President of Eli Lilly & Co. (NYSE: LLY), a global healthcare company, and President of Lilly Bio Medicines, the business within Eli Lilly Company that comprised its neuroscience and immunology divisions. From 2014 to 2016, Ms. Shaw served as U.S. country head and President of Novartis Pharmaceutical Corporation, a global healthcare company, and from 2010 to 2014, as North American region head of Novartis Oncology. Prior to 2010, Ms. Shaw held several leadership positions at Johnson & Johnson, Inc. (NYSE: JNJ). Previously, she served as an executive committee member of the Biotechnology Innovation Organization. Ms. Shaw is also an advisor for Family Reach's Clinical Trial Access Program, which she co founded with her sister (More Moments More Memories) to assist people with cancer access clinical trials. Ms. Shaw holds a B.B.A. in Marketing from Iowa State University and an M.B.A. from the University of Wisconsin.
Andrew Miller

Andrew Miller自2018年8月起担任我们的首席运营官，并于2012年4月至2019年3月担任我们的董事会成员。Miller博士是我们的创始人，在担任我们的首席运营官之前，他于2016年7月至2018年8月担任我们的总裁兼首席执行官。从2008年8月到2016年7月，米勒博士曾在PureTech Health plc担任多个职位，最后担任Vice President，PureTech Health plc的风险合伙人，并担任TAL Medical的首席运营官和Entrega，Inc.的代理首席运营官。他目前是Entrega，Inc.的董事会成员。Miller博士以最高荣誉在伊利诺伊大学（University of Illinois）获得化学工程学士学位，并在麻省理工学院（Massachusetts Institute of Technology）完成化学工程博士学位。


Andrew Miller has served as a member of Kyverna Therapeutics, Inc.'s Board since February 2026. Dr. Miller previously founded Karuna Therapeutics, Inc. ("Karuna"), a biopharmaceutical company developing treatments for psychiatric and neurological conditions. He most recently served as President of Research and Development at Karuna until its $14 billion acquisition by Bristol Myers Squibb in 2024 and previously served as Chief Operating Officer, Chief Executive Officer and as a member of Karuna's Board of Directors. Prior to that, Dr. Miller held senior and executive level positions at PureTech Health plc, Tal Medical and Entrega, Inc. He also served as a member of the board of directors of Entrega, Inc. from 2013 to 2025. Dr. Miller currently serves as the Chairman of the Board at Progentos Therapeutics. He received a B.S. in Chemical Engineering from the University of Illinois with highest honors and completed his Ph.D. in Chemical Engineering at the Massachusetts Institute of Technology.
Andrew Miller自2018年8月起担任我们的首席运营官，并于2012年4月至2019年3月担任我们的董事会成员。Miller博士是我们的创始人，在担任我们的首席运营官之前，他于2016年7月至2018年8月担任我们的总裁兼首席执行官。从2008年8月到2016年7月，米勒博士曾在PureTech Health plc担任多个职位，最后担任Vice President，PureTech Health plc的风险合伙人，并担任TAL Medical的首席运营官和Entrega，Inc.的代理首席运营官。他目前是Entrega，Inc.的董事会成员。Miller博士以最高荣誉在伊利诺伊大学（University of Illinois）获得化学工程学士学位，并在麻省理工学院（Massachusetts Institute of Technology）完成化学工程博士学位。
Andrew Miller has served as a member of Kyverna Therapeutics, Inc.'s Board since February 2026. Dr. Miller previously founded Karuna Therapeutics, Inc. ("Karuna"), a biopharmaceutical company developing treatments for psychiatric and neurological conditions. He most recently served as President of Research and Development at Karuna until its $14 billion acquisition by Bristol Myers Squibb in 2024 and previously served as Chief Operating Officer, Chief Executive Officer and as a member of Karuna's Board of Directors. Prior to that, Dr. Miller held senior and executive level positions at PureTech Health plc, Tal Medical and Entrega, Inc. He also served as a member of the board of directors of Entrega, Inc. from 2013 to 2025. Dr. Miller currently serves as the Chairman of the Board at Progentos Therapeutics. He received a B.S. in Chemical Engineering from the University of Illinois with highest honors and completed his Ph.D. in Chemical Engineering at the Massachusetts Institute of Technology.
Beth Seidenberg

Beth Seidenberg自2024年7月起担任Latigo Biotherapeutics，Inc.董事会成员。Seidenberg博士自2018年9月起担任生命科学风险投资公司Westlake BioPartners的创始董事总经理。自2005年5月以来，塞登伯格博士一直担任由Kleiner Perkins Caufield和风险投资公司Byers，LLC提供咨询的风险投资基金的管理成员，她主要专注于生命科学投资。2002年2月至2005年5月，Seidenberg博士在上市生物技术公司安进公司担任高级副总裁、全球发展主管和首席医疗官。在此之前，塞登伯格博士曾担任多个职位，包括在上市生物制药公司百时美施贵宝公司担任全球发展高级副总裁，在上市生物制药公司默克制药公司担任肺免疫学副总裁。Seidenberg博士曾在一家公众持股的生物技术公司Vera Therapeutics, Inc.的董事会任职，自2016年6月起，Kyverna Therapeutics，Inc.，一家公众持股的生物制药公司，自2018年9月起，Sagimet Biosciences Inc.，一家公众持股的生物技术公司，自2007年4月起，以及其他几家私人持股的生命科学公司。Seidenberg博士此前曾于2020年10月至2025年3月在公众持股的生物制药公司Acelyrin，Inc.、2012年8月至2023年6月在公众持股的生物制药公司Atara Biotherapeutics, Inc.以及于2010年5月至2024年11月在公众持股的生育福利管理公司Progyny, Inc.担任董事会成员。塞登伯格博士在巴纳德学院获得生物学和人类学学士学位，在迈阿密大学医学院获得医学博士学位，并在约翰霍普金斯大学、乔治华盛顿大学和美国国立卫生研究院完成了研究生培训。


Beth Seidenberg has served as a member of Latigo Biotherapeutics, Inc.'s board of directors since July 2024. Dr. Seidenberg has served as a founding Managing Director of Westlake BioPartners, a life sciences venture capital firm, since September 2018. Since May 2005, Dr. Seidenberg has served as Managing Member of venture capital funds advised by Kleiner Perkins Caufield and Byers, LLC, a venture capital firm, where she primarily focuses on life sciences investing. From February 2002 to May 2005, Dr. Seidenberg served as the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen Inc., a publicly held biotechnology company. Prior to that, Dr. Seidenberg held various positions, including as Senior Vice President of Global Development at Bristol Myers Squibb Company, a publicly held biopharmaceutical company, and as Vice President of Pulmonary Immunology at Merck & Co., Inc., a publicly held biopharmaceutical company. Dr. Seidenberg has served on the board of directors of Vera Therapeutics, Inc., a publicly held biotechnology company, since June 2016, Kyverna Therapeutics, Inc., a publicly held biopharmaceutical company, since September 2018, Sagimet Biosciences Inc., a publicly held biotechnology company, since April 2007, and several other privately held life sciences companies. Dr. Seidenberg previously served on the board of directors of Acelyrin, Inc., a publicly held biopharmaceutical company, from October 2020 to March 2025, Atara Biotherapeutics, Inc., a publicly held biopharmaceutical company from August 2012 to June 2023, and Progyny, Inc., a publicly held fertility benefit management company, from May 2010 to November 2024. Dr. Seidenberg earned her B.S. in Biology and Anthropology from Barnard College and her M.D. from the University of Miami School of Medicine and completed her post graduate training at the Johns Hopkins University, George Washington University and the National Institutes of Health.
Beth Seidenberg自2024年7月起担任Latigo Biotherapeutics，Inc.董事会成员。Seidenberg博士自2018年9月起担任生命科学风险投资公司Westlake BioPartners的创始董事总经理。自2005年5月以来，塞登伯格博士一直担任由Kleiner Perkins Caufield和风险投资公司Byers，LLC提供咨询的风险投资基金的管理成员，她主要专注于生命科学投资。2002年2月至2005年5月，Seidenberg博士在上市生物技术公司安进公司担任高级副总裁、全球发展主管和首席医疗官。在此之前，塞登伯格博士曾担任多个职位，包括在上市生物制药公司百时美施贵宝公司担任全球发展高级副总裁，在上市生物制药公司默克制药公司担任肺免疫学副总裁。Seidenberg博士曾在一家公众持股的生物技术公司Vera Therapeutics, Inc.的董事会任职，自2016年6月起，Kyverna Therapeutics，Inc.，一家公众持股的生物制药公司，自2018年9月起，Sagimet Biosciences Inc.，一家公众持股的生物技术公司，自2007年4月起，以及其他几家私人持股的生命科学公司。Seidenberg博士此前曾于2020年10月至2025年3月在公众持股的生物制药公司Acelyrin，Inc.、2012年8月至2023年6月在公众持股的生物制药公司Atara Biotherapeutics, Inc.以及于2010年5月至2024年11月在公众持股的生育福利管理公司Progyny, Inc.担任董事会成员。塞登伯格博士在巴纳德学院获得生物学和人类学学士学位，在迈阿密大学医学院获得医学博士学位，并在约翰霍普金斯大学、乔治华盛顿大学和美国国立卫生研究院完成了研究生培训。
Beth Seidenberg has served as a member of Latigo Biotherapeutics, Inc.'s board of directors since July 2024. Dr. Seidenberg has served as a founding Managing Director of Westlake BioPartners, a life sciences venture capital firm, since September 2018. Since May 2005, Dr. Seidenberg has served as Managing Member of venture capital funds advised by Kleiner Perkins Caufield and Byers, LLC, a venture capital firm, where she primarily focuses on life sciences investing. From February 2002 to May 2005, Dr. Seidenberg served as the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen Inc., a publicly held biotechnology company. Prior to that, Dr. Seidenberg held various positions, including as Senior Vice President of Global Development at Bristol Myers Squibb Company, a publicly held biopharmaceutical company, and as Vice President of Pulmonary Immunology at Merck & Co., Inc., a publicly held biopharmaceutical company. Dr. Seidenberg has served on the board of directors of Vera Therapeutics, Inc., a publicly held biotechnology company, since June 2016, Kyverna Therapeutics, Inc., a publicly held biopharmaceutical company, since September 2018, Sagimet Biosciences Inc., a publicly held biotechnology company, since April 2007, and several other privately held life sciences companies. Dr. Seidenberg previously served on the board of directors of Acelyrin, Inc., a publicly held biopharmaceutical company, from October 2020 to March 2025, Atara Biotherapeutics, Inc., a publicly held biopharmaceutical company from August 2012 to June 2023, and Progyny, Inc., a publicly held fertility benefit management company, from May 2010 to November 2024. Dr. Seidenberg earned her B.S. in Biology and Anthropology from Barnard College and her M.D. from the University of Miami School of Medicine and completed her post graduate training at the Johns Hopkins University, George Washington University and the National Institutes of Health.
Warner Biddle

Warner Weston Biddle自2024年9月起担任首席执行官和董事会成员。Biddle Previoly先生于2020年8月至2024年9月在Kite Pharma，Inc.工作，曾担任高级副总裁兼全球商务主管。在此之前，Biddle先生曾于2018年1月至2020年8月在基因泰克担任副总裁兼乳腺癌/妇科和皮肤癌特许经营的特许经营负责人。在他多产的任期内，他领导了跨职能战略，并为几个关键的商业和管道产品推出了产品，同时推动了产品组合的显着增长。在担任肿瘤学职务之前，Biddle先生曾于2013年11月至2015年12月在基因泰克担任眼科销售和营销副总裁，还曾在诺华和葛兰素史克的多个治疗疾病领域担任欧洲和加拿大的多个全球领导职务。比德尔先生以优异的成绩获得了萨斯喀彻温大学的商业学士学位。


Warner Biddle has served as Kyverna Therapeutics, Inc.'s Chief Executive Officer and a member of Kyverna Therapeutics, Inc.'s Board since September 2024. Mr. Biddle previously worked at Kite Pharma, Inc. from August 2020 to September 2024, where he served as Senior Vice President and Global Head of Commercial. Prior to that, Mr. Biddle served as Vice President and Franchise Head for the Breast/Gynecologic and Skin Cancer Franchises at Genentech from January 2018 to August 2020. During his prolific tenure, he led the cross functional strategy and launches for several key commercial and pipeline products while driving significant portfolio growth. Prior to his oncology roles, Mr. Biddle served as Vice President, Sales and Marketing for Ophthalmology at Genentech from November 2013 to December 2015, and also held various global leadership roles in Europe and Canada across multiple therapeutic disease areas at Novartis and GlaxoSmithKline. Mr. Biddle earned a Bachelor's Degree in Commerce with Honors from the University of Saskatchewan.
Warner Weston Biddle自2024年9月起担任首席执行官和董事会成员。Biddle Previoly先生于2020年8月至2024年9月在Kite Pharma，Inc.工作，曾担任高级副总裁兼全球商务主管。在此之前，Biddle先生曾于2018年1月至2020年8月在基因泰克担任副总裁兼乳腺癌/妇科和皮肤癌特许经营的特许经营负责人。在他多产的任期内，他领导了跨职能战略，并为几个关键的商业和管道产品推出了产品，同时推动了产品组合的显着增长。在担任肿瘤学职务之前，Biddle先生曾于2013年11月至2015年12月在基因泰克担任眼科销售和营销副总裁，还曾在诺华和葛兰素史克的多个治疗疾病领域担任欧洲和加拿大的多个全球领导职务。比德尔先生以优异的成绩获得了萨斯喀彻温大学的商业学士学位。
Warner Biddle has served as Kyverna Therapeutics, Inc.'s Chief Executive Officer and a member of Kyverna Therapeutics, Inc.'s Board since September 2024. Mr. Biddle previously worked at Kite Pharma, Inc. from August 2020 to September 2024, where he served as Senior Vice President and Global Head of Commercial. Prior to that, Mr. Biddle served as Vice President and Franchise Head for the Breast/Gynecologic and Skin Cancer Franchises at Genentech from January 2018 to August 2020. During his prolific tenure, he led the cross functional strategy and launches for several key commercial and pipeline products while driving significant portfolio growth. Prior to his oncology roles, Mr. Biddle served as Vice President, Sales and Marketing for Ophthalmology at Genentech from November 2013 to December 2015, and also held various global leadership roles in Europe and Canada across multiple therapeutic disease areas at Novartis and GlaxoSmithKline. Mr. Biddle earned a Bachelor's Degree in Commerce with Honors from the University of Saskatchewan.
Mert Aktar

Mert Aktar自2024年10月起担任董事会成员。Aktar先生是一位成就卓著的生命科学行业高管，在制药和生物技术领域将科学与biness联系起来方面拥有超过tnty年的跨国经验。他自2024年2月起担任Receptive Bio，Inc.的首席执行官，该公司是一家位于南加州的私营生物技术公司。在加入Receptive Bio，Inc.之前，Aktar先生于2020年4月至2023年9月期间担任Kite Pharma, Inc.的高级副总裁兼企业发展与战略全球主管，在那里他为塑造Kite的未来方向并将其确立为细胞治疗的全球领导者发挥了关键的领导作用。Aktar先生领导的数字交易加强了Kite的研发组合，包括在亚洲的扩张，促进监管机构批准和在中国首个自体细胞治疗产品的商业推出，以及从Daiichi Sankyo转让商业权利和监管机构批准并在日本商业推出Yescarta。在加入Kite之前，Aktar先生曾于2019年5月至2020年3月在Unum Therapeutics Inc.担任副总裁兼Biness发展和企业发展负责人。在此之前，Aktar先生于2011年4月至2019年5月期间在Shire PLC（现为Takeda Pharmaceutical Company Limited）担任多个高级领导职务，最近一次是在2017年11月至2019年5月期间担任血液学和免疫学Biness Development全球主管。在Shire任职期间，Aktar先生为该公司收购Baxalta Inc.和Dyax Corp.提供了便利，并精心策划了Shire首次SEC注册债务发行。Aktar先生在各种模式（细胞疗法、基因疗法、基于核苷酸的疗法、抗体疗法和小分子）和治疗领域（肿瘤学、血液学、免疫学、罕见遗传病和神经科学）的大型生物技术和制药组织担任高级领导职务。Aktar先生自2024年1月起担任ReAlta Life Sciences，Inc.的董事会成员。Aktar先生拥有麻省理工学院斯隆管理学院MBA学位、伍斯特理工学院化学工程学士学位和塔夫茨大学工程管理硕士学位。


Mert Aktar has served as a member of Kyverna Therapeutics, Inc.'s Board since October 2024. Mr. Aktar is an accomplished life sciences industry executive with over twenty years of multinational experience in bridging science and business in pharmaceuticals and biotechnology. He has served as Chief Executive Officer of Receptive Bio, Inc., a privately held biotechnology company based in Southern California, since February 2024. Prior to joining Receptive Bio, Inc., Mr. Aktar was the Senior Vice President and Global Head of Corporate Development & Strategy at Kite Pharma, Inc., from April 2020 to September 2023, where he played a key leadership role in shaping the future direction of Kite and establishing it as a global leader in cell therapy. Mr. Aktar led numerous deals strengthening Kite's R&D portfolio, including expansion in Asia, facilitating regulatory approval and commercial launch of the first autologous cell therapy product in China, and transfer of commercial rights from Daiichi Sankyo and regulatory approval and commercial launch of Yescarta in Japan. Prior to joining Kite, Mr. Aktar served as Vice President and Head of Business Development and Corporate Development at Unum Therapeutics Inc. from May 2019 to March 2020. Prior to that, Mr. Aktar held a number of senior leadership positions at Shire plc (now Takeda Pharmaceutical Company Limited) from April 2011 to May 2019, most recently serving as the Global Head of Hematology and Immunology Business Development from November 2017 to May 2019. While at Shire, Mr. Aktar facilitated the company's acquisitions of Baxalta Inc. and Dyax Corp., and orchestrated Shire's inaugural SEC registered debt offering. Mr. Aktar held senior leadership positions at large biotech and pharma organizations across diverse modalities (cell therapy, gene therapy, nucleotide based therapies, antibody therapeutics and small molecules) and therapeutic areas (oncology, hematology, immunology, rare genetic diseases and neuroscience). Mr. Aktar has served on the board of directors of ReAlta Life Sciences, Inc. since January 2024. Mr. Aktar holds an MBA from MIT Sloan School of Management, a B.S. in Chemical Engineering from Worcester Polytechnic Institute, and an M.S. in Engineering Management from Tufts University.
Mert Aktar自2024年10月起担任董事会成员。Aktar先生是一位成就卓著的生命科学行业高管，在制药和生物技术领域将科学与biness联系起来方面拥有超过tnty年的跨国经验。他自2024年2月起担任Receptive Bio，Inc.的首席执行官，该公司是一家位于南加州的私营生物技术公司。在加入Receptive Bio，Inc.之前，Aktar先生于2020年4月至2023年9月期间担任Kite Pharma, Inc.的高级副总裁兼企业发展与战略全球主管，在那里他为塑造Kite的未来方向并将其确立为细胞治疗的全球领导者发挥了关键的领导作用。Aktar先生领导的数字交易加强了Kite的研发组合，包括在亚洲的扩张，促进监管机构批准和在中国首个自体细胞治疗产品的商业推出，以及从Daiichi Sankyo转让商业权利和监管机构批准并在日本商业推出Yescarta。在加入Kite之前，Aktar先生曾于2019年5月至2020年3月在Unum Therapeutics Inc.担任副总裁兼Biness发展和企业发展负责人。在此之前，Aktar先生于2011年4月至2019年5月期间在Shire PLC（现为Takeda Pharmaceutical Company Limited）担任多个高级领导职务，最近一次是在2017年11月至2019年5月期间担任血液学和免疫学Biness Development全球主管。在Shire任职期间，Aktar先生为该公司收购Baxalta Inc.和Dyax Corp.提供了便利，并精心策划了Shire首次SEC注册债务发行。Aktar先生在各种模式（细胞疗法、基因疗法、基于核苷酸的疗法、抗体疗法和小分子）和治疗领域（肿瘤学、血液学、免疫学、罕见遗传病和神经科学）的大型生物技术和制药组织担任高级领导职务。Aktar先生自2024年1月起担任ReAlta Life Sciences，Inc.的董事会成员。Aktar先生拥有麻省理工学院斯隆管理学院MBA学位、伍斯特理工学院化学工程学士学位和塔夫茨大学工程管理硕士学位。
Mert Aktar has served as a member of Kyverna Therapeutics, Inc.'s Board since October 2024. Mr. Aktar is an accomplished life sciences industry executive with over twenty years of multinational experience in bridging science and business in pharmaceuticals and biotechnology. He has served as Chief Executive Officer of Receptive Bio, Inc., a privately held biotechnology company based in Southern California, since February 2024. Prior to joining Receptive Bio, Inc., Mr. Aktar was the Senior Vice President and Global Head of Corporate Development & Strategy at Kite Pharma, Inc., from April 2020 to September 2023, where he played a key leadership role in shaping the future direction of Kite and establishing it as a global leader in cell therapy. Mr. Aktar led numerous deals strengthening Kite's R&D portfolio, including expansion in Asia, facilitating regulatory approval and commercial launch of the first autologous cell therapy product in China, and transfer of commercial rights from Daiichi Sankyo and regulatory approval and commercial launch of Yescarta in Japan. Prior to joining Kite, Mr. Aktar served as Vice President and Head of Business Development and Corporate Development at Unum Therapeutics Inc. from May 2019 to March 2020. Prior to that, Mr. Aktar held a number of senior leadership positions at Shire plc (now Takeda Pharmaceutical Company Limited) from April 2011 to May 2019, most recently serving as the Global Head of Hematology and Immunology Business Development from November 2017 to May 2019. While at Shire, Mr. Aktar facilitated the company's acquisitions of Baxalta Inc. and Dyax Corp., and orchestrated Shire's inaugural SEC registered debt offering. Mr. Aktar held senior leadership positions at large biotech and pharma organizations across diverse modalities (cell therapy, gene therapy, nucleotide based therapies, antibody therapeutics and small molecules) and therapeutic areas (oncology, hematology, immunology, rare genetic diseases and neuroscience). Mr. Aktar has served on the board of directors of ReAlta Life Sciences, Inc. since January 2024. Mr. Aktar holds an MBA from MIT Sloan School of Management, a B.S. in Chemical Engineering from Worcester Polytechnic Institute, and an M.S. in Engineering Management from Tufts University.
Sravan Emany

Sravan Emany，自2024年12月起担任Beam Therapeutics Inc.（“Beam”）的首席财务官。在加入Beam之前，Emany先生自2021年12月起担任Ironwood Pharmaceuticals, Inc.（一家全球医疗保健上市公司）的首席财务官和首席运营官。在此之前，Emany先生于2020年3月至2021年12月担任公司副总裁、商业卓越和Integra LifeSciences Holdings Corporation（“Integra”）的首席战略官，该公司是一家全球医疗保健上市公司，并于2018年2月至2020年3月担任战略、财务和投资者关系副总裁。在加入Integra之前，Emany先生曾在美国银行和美国银行证券（前身为美银美林）担任多个并购投资银行职务近十年，最终在并购集团担任董事总经理，领导了医疗保健领域的众多并购活动。他还担任过其他各种金融职务，包括在高盛萨克斯集团和摩根士丹利任职。Emany先生在Assertio Holdings, Inc.（纳斯达克：ASRT）的董事会任职。他拥有约翰霍普金斯大学国际关系学士学位和约翰霍普金斯大学高级国际研究学院国际关系和国际经济学硕士学位。


Sravan Emany has served as a member of Kyverna Therapeutics, Inc.'s Board since February 2026. Mr. Emany has served as the Chief Financial Officer of Beam Therapeutics Inc. (Nasdaq: BEAM) since December 2024. Prior to that, Mr. Emany served as Corporate Vice President, Commercial Excellence and Chief Strategy Officer of Integra LifeSciences Holdings Corporation ("Integra"), a publicly held global healthcare company, from March 2020 to December 2021, and as Vice President of Strategy, Treasury and Investor Relations from February 2018 to March 2020. Prior to Integra, Mr. Emany served in various mergers and acquisitions investment banking roles in Bank of America and BofA Securities, formerly Bank of America Merrill Lynch, for nearly a decade, culminating in his service as Managing Director in the mergers and acquisitions group, where he led numerous mergers and acquisitions in the healthcare sector. He also served in various other financial roles, including with Goldman Sachs Group and Morgan Stanley. Mr. Emany serves on the board of directors of Assertio Holdings, Inc. (Nasdaq: ASRT). He holds a B.A. in international relations from The Johns Hopkins University and an M.A. in international relations and international economics from The Johns Hopkins School of Advanced International Studies.
Sravan Emany，自2024年12月起担任Beam Therapeutics Inc.（“Beam”）的首席财务官。在加入Beam之前，Emany先生自2021年12月起担任Ironwood Pharmaceuticals, Inc.（一家全球医疗保健上市公司）的首席财务官和首席运营官。在此之前，Emany先生于2020年3月至2021年12月担任公司副总裁、商业卓越和Integra LifeSciences Holdings Corporation（“Integra”）的首席战略官，该公司是一家全球医疗保健上市公司，并于2018年2月至2020年3月担任战略、财务和投资者关系副总裁。在加入Integra之前，Emany先生曾在美国银行和美国银行证券（前身为美银美林）担任多个并购投资银行职务近十年，最终在并购集团担任董事总经理，领导了医疗保健领域的众多并购活动。他还担任过其他各种金融职务，包括在高盛萨克斯集团和摩根士丹利任职。Emany先生在Assertio Holdings, Inc.（纳斯达克：ASRT）的董事会任职。他拥有约翰霍普金斯大学国际关系学士学位和约翰霍普金斯大学高级国际研究学院国际关系和国际经济学硕士学位。
Sravan Emany has served as a member of Kyverna Therapeutics, Inc.'s Board since February 2026. Mr. Emany has served as the Chief Financial Officer of Beam Therapeutics Inc. (Nasdaq: BEAM) since December 2024. Prior to that, Mr. Emany served as Corporate Vice President, Commercial Excellence and Chief Strategy Officer of Integra LifeSciences Holdings Corporation ("Integra"), a publicly held global healthcare company, from March 2020 to December 2021, and as Vice President of Strategy, Treasury and Investor Relations from February 2018 to March 2020. Prior to Integra, Mr. Emany served in various mergers and acquisitions investment banking roles in Bank of America and BofA Securities, formerly Bank of America Merrill Lynch, for nearly a decade, culminating in his service as Managing Director in the mergers and acquisitions group, where he led numerous mergers and acquisitions in the healthcare sector. He also served in various other financial roles, including with Goldman Sachs Group and Morgan Stanley. Mr. Emany serves on the board of directors of Assertio Holdings, Inc. (Nasdaq: ASRT). He holds a B.A. in international relations from The Johns Hopkins University and an M.A. in international relations and international economics from The Johns Hopkins School of Advanced International Studies.
Fred E. Cohen

Fred E. Cohen，自2018年9月起担任Kyverna Therapeutics， Inc.董事会成员。自2017年11月以来，Cohen博士一直担任Vida Ventures（他于2017年共同创立的风险投资公司）的高级常务董事。他也曾担任Monograph Capital Partners（生物技术风险投资基金）的联合创始人兼董事长（2021年7月以来）。他目前担任TPG的高级顾问，在那里他曾担任TPG Biotechnology（生命科学风险投资基金）的合伙人和创始人（从2001年到2016年）。Cohen博士也是私人持有的Cell Design Labs的联合创始人兼执行主席，该公司于2017年12月被Gilead Sciences， Inc.（纳斯达克股票代码：GILD）收购。从1980年到2014年，Cohen博士在加州大学旧金山分校（UCSF）担任研究科学家、住院患者内科医生、咨询内分泌学家、内分泌学和代谢科主任等职务。他的研究兴趣包括基于结构的药物设计、朊病毒疾病、计算生物学和杂多聚合物化学。Cohen博士发表了200多篇同行评议文章，作为10多项专利的共同发明人参与，并担任多个国际科学期刊的编辑或编辑委员会成员。他持有Yale University的分子生物物理学和生物化学学士学位。他获得了斯坦福大学的医学博士学位，并在UCSF接受了内科和内分泌学的博士后和研究生医学培训。他是美国医师学会和美国医学信息学学会的成员，也是美国临床研究学会和美国医师协会的成员。Cohen博士因其工作获得了多个奖项，包括Searle奖学金、内分泌学会和西方临床研究学会颁发的青年研究者奖，以及LVMH Science pour l’art奖（与Stanley Prusiner共享）。科恩博士于2004年当选为美国国家医学院院士，2008年当选为美国艺术与科学学院院士。Cohen博士目前担任多个生物技术和制药组织的董事会成员，包括CareDx， Inc.（纳斯达克代码：CDNA）， Progyny, Inc.（纳斯达克代码：PGNY）， Intellia Therapeutics, Inc.（纳斯达克代码：NTLA）和UroGen Pharma Ltd.（纳斯达克代码：URGN）。他是Quintiles Transnational（与IQVIA Holdings（纽约证券交易所代码：IQV）合并）、Biocryst（纳斯达克代码：BCRX）、Genomic Health（被Exact Sciences Corp.收购）（纳斯达克代码：GHDX）、Tandem Diabetes Care, Inc.（纳斯达克代码：TNDM）、Five Prime Therapeutics, Inc.（纳斯达克代码：FPRX，被Amgen Inc.收购）、Roka Biosciences（纳斯达克代码：Roka）和Veracyte， Inc.（纳斯达克代码：VCYT）的前任董事会成员。


Fred E. Cohen has served as a member of Kyverna Therapeutics, Inc.'s Board since September 2018. Since November 2017, Dr. Cohen has served as a Senior Managing Director of Vida Ventures, a venture capital firm that he co founded in 2017. Dr. Cohen has also served as a cofounder and Chairman of Monograph Capital Partners, a biotechnology venture capital fund, since July 2021. Dr. Cohen currently serves as a Senior Advisor to TPG, where he previously served as a Partner and founder of TPG Biotechnology, a life science venture capital fund, from 2001 to 2016. Dr. Cohen was also a co founder and executive chairperson of privately held Cell Design Labs, which was acquired by Gilead Sciences, Inc. (Nasdaq: GILD) in December 2017. From 1980 through 2014, Dr. Cohen was at the University of California, San Francisco (UCSF), where he held various responsibilities as a research scientist, an Internist for hospitalized patients, a consulting Endocrinologist and as the Chief of the Division of Endocrinology and Metabolism. Dr. Cohen's research interests included structure based drug design, prion diseases, computational biology and heteropolymer chemistry. Dr. Cohen has published over 200 peer reviewed articles, participated as a co inventor on over 10 patents and has served as an editor or editorial board member of several international scientific journals. Dr. Cohen received his Bachelor of Science degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular Biophysics from the University of Oxford on a Rhodes Scholarship, his M.D. from Stanford University and his postdoctoral training and postgraduate medical training in Internal Medicine and Endocrinology at UCSF. He is a Fellow of the American College of Physicians and the American College of Medical Informatics and a member of the American Society for Clinical Investigation and Association of American Physicians. Dr. Cohen has received several awards for his work, including a Searle Scholarship, Young Investigator Awards from the Endocrine Society and the Western Society for Clinical Investigation and the LVMH Science pour l'art prize (shared with Stanley Prusiner). Dr. Cohen was elected to the National Academy of Medicine in 2004, and the American Academy of Arts and Sciences in 2008. Dr. Cohen currently serves on the boards of directors of several biotechnology and pharmaceutical organizations, including CareDx, Inc. (Nasdaq: CDNA) and Intellia Therapeutics, Inc. (Nasdaq: NTLA). He is a past member of the boards of UroGen Pharma Ltd. (Nasdaq: URGN), Quintiles Transnational (merged with IQVIA Holdings (NYSE: IQV)), Biocryst (Nasdaq: BCRX), Genomic Health (acquired by Exact Sciences Corp.) (Nasdaq: GHDX), Tandem Diabetes Care, Inc. (Nasdaq: TNDM), Five Prime Therapeutics, Inc. (Nasdaq: FPRX, acquired by Amgen Inc.), Progyny, Inc. (Nasdaq: PGNY), Roka Bioscience, Inc. (Nasdaq: ROKA) and Veracyte, Inc. (Nasdaq: VCYT).
Fred E. Cohen，自2018年9月起担任Kyverna Therapeutics， Inc.董事会成员。自2017年11月以来，Cohen博士一直担任Vida Ventures（他于2017年共同创立的风险投资公司）的高级常务董事。他也曾担任Monograph Capital Partners（生物技术风险投资基金）的联合创始人兼董事长（2021年7月以来）。他目前担任TPG的高级顾问，在那里他曾担任TPG Biotechnology（生命科学风险投资基金）的合伙人和创始人（从2001年到2016年）。Cohen博士也是私人持有的Cell Design Labs的联合创始人兼执行主席，该公司于2017年12月被Gilead Sciences， Inc.（纳斯达克股票代码：GILD）收购。从1980年到2014年，Cohen博士在加州大学旧金山分校（UCSF）担任研究科学家、住院患者内科医生、咨询内分泌学家、内分泌学和代谢科主任等职务。他的研究兴趣包括基于结构的药物设计、朊病毒疾病、计算生物学和杂多聚合物化学。Cohen博士发表了200多篇同行评议文章，作为10多项专利的共同发明人参与，并担任多个国际科学期刊的编辑或编辑委员会成员。他持有Yale University的分子生物物理学和生物化学学士学位。他获得了斯坦福大学的医学博士学位，并在UCSF接受了内科和内分泌学的博士后和研究生医学培训。他是美国医师学会和美国医学信息学学会的成员，也是美国临床研究学会和美国医师协会的成员。Cohen博士因其工作获得了多个奖项，包括Searle奖学金、内分泌学会和西方临床研究学会颁发的青年研究者奖，以及LVMH Science pour l’art奖（与Stanley Prusiner共享）。科恩博士于2004年当选为美国国家医学院院士，2008年当选为美国艺术与科学学院院士。Cohen博士目前担任多个生物技术和制药组织的董事会成员，包括CareDx， Inc.（纳斯达克代码：CDNA）， Progyny, Inc.（纳斯达克代码：PGNY）， Intellia Therapeutics, Inc.（纳斯达克代码：NTLA）和UroGen Pharma Ltd.（纳斯达克代码：URGN）。他是Quintiles Transnational（与IQVIA Holdings（纽约证券交易所代码：IQV）合并）、Biocryst（纳斯达克代码：BCRX）、Genomic Health（被Exact Sciences Corp.收购）（纳斯达克代码：GHDX）、Tandem Diabetes Care, Inc.（纳斯达克代码：TNDM）、Five Prime Therapeutics, Inc.（纳斯达克代码：FPRX，被Amgen Inc.收购）、Roka Biosciences（纳斯达克代码：Roka）和Veracyte， Inc.（纳斯达克代码：VCYT）的前任董事会成员。
Fred E. Cohen has served as a member of Kyverna Therapeutics, Inc.'s Board since September 2018. Since November 2017, Dr. Cohen has served as a Senior Managing Director of Vida Ventures, a venture capital firm that he co founded in 2017. Dr. Cohen has also served as a cofounder and Chairman of Monograph Capital Partners, a biotechnology venture capital fund, since July 2021. Dr. Cohen currently serves as a Senior Advisor to TPG, where he previously served as a Partner and founder of TPG Biotechnology, a life science venture capital fund, from 2001 to 2016. Dr. Cohen was also a co founder and executive chairperson of privately held Cell Design Labs, which was acquired by Gilead Sciences, Inc. (Nasdaq: GILD) in December 2017. From 1980 through 2014, Dr. Cohen was at the University of California, San Francisco (UCSF), where he held various responsibilities as a research scientist, an Internist for hospitalized patients, a consulting Endocrinologist and as the Chief of the Division of Endocrinology and Metabolism. Dr. Cohen's research interests included structure based drug design, prion diseases, computational biology and heteropolymer chemistry. Dr. Cohen has published over 200 peer reviewed articles, participated as a co inventor on over 10 patents and has served as an editor or editorial board member of several international scientific journals. Dr. Cohen received his Bachelor of Science degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular Biophysics from the University of Oxford on a Rhodes Scholarship, his M.D. from Stanford University and his postdoctoral training and postgraduate medical training in Internal Medicine and Endocrinology at UCSF. He is a Fellow of the American College of Physicians and the American College of Medical Informatics and a member of the American Society for Clinical Investigation and Association of American Physicians. Dr. Cohen has received several awards for his work, including a Searle Scholarship, Young Investigator Awards from the Endocrine Society and the Western Society for Clinical Investigation and the LVMH Science pour l'art prize (shared with Stanley Prusiner). Dr. Cohen was elected to the National Academy of Medicine in 2004, and the American Academy of Arts and Sciences in 2008. Dr. Cohen currently serves on the boards of directors of several biotechnology and pharmaceutical organizations, including CareDx, Inc. (Nasdaq: CDNA) and Intellia Therapeutics, Inc. (Nasdaq: NTLA). He is a past member of the boards of UroGen Pharma Ltd. (Nasdaq: URGN), Quintiles Transnational (merged with IQVIA Holdings (NYSE: IQV)), Biocryst (Nasdaq: BCRX), Genomic Health (acquired by Exact Sciences Corp.) (Nasdaq: GHDX), Tandem Diabetes Care, Inc. (Nasdaq: TNDM), Five Prime Therapeutics, Inc. (Nasdaq: FPRX, acquired by Amgen Inc.), Progyny, Inc. (Nasdaq: PGNY), Roka Bioscience, Inc. (Nasdaq: ROKA) and Veracyte, Inc. (Nasdaq: VCYT).

高管简历

中英对照 |  中文 |  英文
Christi Shaw

Christi Shaw是Eli Lilly公司的高级副总裁，Eli Lilly公司是一家全球医疗保健公司，也是礼来生物医药公司的总裁，礼来公司是Eli Lilly公司的业务部门，其中包括自2017年4月以来一直担任的神经科学和免疫学。2014年至2016年，Shaw女士担任全球医疗保健公司Novartis Pharmaceutical Corporation的美国区域负责人和总裁，并于2010年至2014年担任诺华公司的北美地区负责人。2010年之前，Shaw女士在强生公司担任多个领导职务。Shaw女士还担任生物技术创新组织的执行董事会成员，并且是More Moments More Memories Foundation的联合创始人。Shaw女士拥有爱荷华州立大学市场营销学士学位和威斯康星大学工商管理硕士学位。


Christi Shaw has served as a member of Kyverna Therapeutics, Inc.'s Board since September 2024 and as Executive Chairperson of Kyverna Therapeutics, Inc.'s Board since January 12, 2026. Ms. Shaw is a seasoned healthcare executive with over 30 years of experience in the biopharmaceutical industry. Most recently, she served as Chief Executive Officer of Kite Pharma, Inc., a Gilead company specializing in the development of cancer immunotherapies, from August 2019 to March 2023. Ms. Shaw has served on the board of directors of Beam Therapeutics Inc. (Nasdaq: BEAM) since December 2023 and on the board of directors for ReAlta Life Sciences, Inc. from January 2024 until September 2025. Ms. Shaw also served as a director of Avantor, Inc. (NYSE: AVTR) from November 2018 through May 2024. From April 2017 to August 2019, she served as Senior Vice President of Eli Lilly & Co. (NYSE: LLY), a global healthcare company, and President of Lilly Bio Medicines, the business within Eli Lilly Company that comprised its neuroscience and immunology divisions. From 2014 to 2016, Ms. Shaw served as U.S. country head and President of Novartis Pharmaceutical Corporation, a global healthcare company, and from 2010 to 2014, as North American region head of Novartis Oncology. Prior to 2010, Ms. Shaw held several leadership positions at Johnson & Johnson, Inc. (NYSE: JNJ). Previously, she served as an executive committee member of the Biotechnology Innovation Organization. Ms. Shaw is also an advisor for Family Reach's Clinical Trial Access Program, which she co founded with her sister (More Moments More Memories) to assist people with cancer access clinical trials. Ms. Shaw holds a B.B.A. in Marketing from Iowa State University and an M.B.A. from the University of Wisconsin.
Christi Shaw是Eli Lilly公司的高级副总裁，Eli Lilly公司是一家全球医疗保健公司，也是礼来生物医药公司的总裁，礼来公司是Eli Lilly公司的业务部门，其中包括自2017年4月以来一直担任的神经科学和免疫学。2014年至2016年，Shaw女士担任全球医疗保健公司Novartis Pharmaceutical Corporation的美国区域负责人和总裁，并于2010年至2014年担任诺华公司的北美地区负责人。2010年之前，Shaw女士在强生公司担任多个领导职务。Shaw女士还担任生物技术创新组织的执行董事会成员，并且是More Moments More Memories Foundation的联合创始人。Shaw女士拥有爱荷华州立大学市场营销学士学位和威斯康星大学工商管理硕士学位。
Christi Shaw has served as a member of Kyverna Therapeutics, Inc.'s Board since September 2024 and as Executive Chairperson of Kyverna Therapeutics, Inc.'s Board since January 12, 2026. Ms. Shaw is a seasoned healthcare executive with over 30 years of experience in the biopharmaceutical industry. Most recently, she served as Chief Executive Officer of Kite Pharma, Inc., a Gilead company specializing in the development of cancer immunotherapies, from August 2019 to March 2023. Ms. Shaw has served on the board of directors of Beam Therapeutics Inc. (Nasdaq: BEAM) since December 2023 and on the board of directors for ReAlta Life Sciences, Inc. from January 2024 until September 2025. Ms. Shaw also served as a director of Avantor, Inc. (NYSE: AVTR) from November 2018 through May 2024. From April 2017 to August 2019, she served as Senior Vice President of Eli Lilly & Co. (NYSE: LLY), a global healthcare company, and President of Lilly Bio Medicines, the business within Eli Lilly Company that comprised its neuroscience and immunology divisions. From 2014 to 2016, Ms. Shaw served as U.S. country head and President of Novartis Pharmaceutical Corporation, a global healthcare company, and from 2010 to 2014, as North American region head of Novartis Oncology. Prior to 2010, Ms. Shaw held several leadership positions at Johnson & Johnson, Inc. (NYSE: JNJ). Previously, she served as an executive committee member of the Biotechnology Innovation Organization. Ms. Shaw is also an advisor for Family Reach's Clinical Trial Access Program, which she co founded with her sister (More Moments More Memories) to assist people with cancer access clinical trials. Ms. Shaw holds a B.B.A. in Marketing from Iowa State University and an M.B.A. from the University of Wisconsin.
Marc Grasso

Marc Grasso，最近于2022年2月至2025年6月在临床阶段的生物技术公司Alector, Inc.担任首席财务官。在此之前，Grasso博士于2018年8月至2022年2月担任临床阶段生物制药公司Kura Oncology，Inc的首席财务官和首席商务官。2013年3月至2018年8月，担任投资银行和金融服务公司Stifel Financial Corp.的董事总经理，负责建设和管理西海岸生命科学和生物技术投行业务。2010年6月至2013年2月，格拉索博士在瑞银 AG担任全球医疗保健集团投资银行业务董事总经理，专注于生物技术领域。从2008年5月到2010年6月，Grasso博士在Leerink Swann LLC（现为Leerink Partners LLC）担任投资银行业务董事总经理，Leerink Swann LLC是一家专注于医疗保健领域的专业投资银行，在该领域他在西海岸扩展其特许经营权方面发挥了重要作用。在此之前，Grasso博士曾在摩根士丹利、瑞士信贷第一波士顿、德意志银行 Alex. Brown Inc.担任关键职位。Grasso博士获得约翰霍普金斯大学医学院的医学博士学位。他以优异的成绩获得了普林斯顿大学分子生物学学士学位。


Marc Grasso has served as Kyverna Therapeutics, Inc.'s Chief Financial Officer since June 2025. Prior to joining Kyverna, Dr. Grasso most recently served as Chief Financial Officer of Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company from February 2022 to June 2025. Prior to that, Dr. Grasso served as Chief Financial Officer and Chief Business Officer of Kura Oncology, Inc (Nasdaq: KURA), a clinical stage biopharmaceutical company, from August 2018 to February 2022. From March 2013 to August 2018, he served as Managing Director of Stifel Financial Corp. (NYSE: SF), an investment bank and financial services company, where he was responsible for building and managing the west coast life sciences and biotechnology investment banking business. From June 2010 to February 2013, Dr. Grasso was Managing Director of Investment Banking in the Global Healthcare Group at UBS Group AG (NYSE: UBS), focusing on the biotechnology sector. From May 2008 to June 2010, Dr. Grasso was Managing Director of Investment Banking at Leerink Swann LLC (now Leerink Partners LLC), a specialist investment bank focused on the healthcare sector, where he was instrumental in the west coast expansion of its franchise. Prior to that, Dr. Grasso held key positions at Morgan Stanley, Credit Suisse First Boston, and Deutsche Bank Alex. Brown Inc. Dr. Grasso received his M.D. from The Johns Hopkins University School of Medicine. He obtained an A.B. in molecular biology with honors from Princeton University.
Marc Grasso，最近于2022年2月至2025年6月在临床阶段的生物技术公司Alector, Inc.担任首席财务官。在此之前，Grasso博士于2018年8月至2022年2月担任临床阶段生物制药公司Kura Oncology，Inc的首席财务官和首席商务官。2013年3月至2018年8月，担任投资银行和金融服务公司Stifel Financial Corp.的董事总经理，负责建设和管理西海岸生命科学和生物技术投行业务。2010年6月至2013年2月，格拉索博士在瑞银 AG担任全球医疗保健集团投资银行业务董事总经理，专注于生物技术领域。从2008年5月到2010年6月，Grasso博士在Leerink Swann LLC（现为Leerink Partners LLC）担任投资银行业务董事总经理，Leerink Swann LLC是一家专注于医疗保健领域的专业投资银行，在该领域他在西海岸扩展其特许经营权方面发挥了重要作用。在此之前，Grasso博士曾在摩根士丹利、瑞士信贷第一波士顿、德意志银行 Alex. Brown Inc.担任关键职位。Grasso博士获得约翰霍普金斯大学医学院的医学博士学位。他以优异的成绩获得了普林斯顿大学分子生物学学士学位。
Marc Grasso has served as Kyverna Therapeutics, Inc.'s Chief Financial Officer since June 2025. Prior to joining Kyverna, Dr. Grasso most recently served as Chief Financial Officer of Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company from February 2022 to June 2025. Prior to that, Dr. Grasso served as Chief Financial Officer and Chief Business Officer of Kura Oncology, Inc (Nasdaq: KURA), a clinical stage biopharmaceutical company, from August 2018 to February 2022. From March 2013 to August 2018, he served as Managing Director of Stifel Financial Corp. (NYSE: SF), an investment bank and financial services company, where he was responsible for building and managing the west coast life sciences and biotechnology investment banking business. From June 2010 to February 2013, Dr. Grasso was Managing Director of Investment Banking in the Global Healthcare Group at UBS Group AG (NYSE: UBS), focusing on the biotechnology sector. From May 2008 to June 2010, Dr. Grasso was Managing Director of Investment Banking at Leerink Swann LLC (now Leerink Partners LLC), a specialist investment bank focused on the healthcare sector, where he was instrumental in the west coast expansion of its franchise. Prior to that, Dr. Grasso held key positions at Morgan Stanley, Credit Suisse First Boston, and Deutsche Bank Alex. Brown Inc. Dr. Grasso received his M.D. from The Johns Hopkins University School of Medicine. He obtained an A.B. in molecular biology with honors from Princeton University.
Warner Biddle

Warner Weston Biddle自2024年9月起担任首席执行官和董事会成员。Biddle Previoly先生于2020年8月至2024年9月在Kite Pharma，Inc.工作，曾担任高级副总裁兼全球商务主管。在此之前，Biddle先生曾于2018年1月至2020年8月在基因泰克担任副总裁兼乳腺癌/妇科和皮肤癌特许经营的特许经营负责人。在他多产的任期内，他领导了跨职能战略，并为几个关键的商业和管道产品推出了产品，同时推动了产品组合的显着增长。在担任肿瘤学职务之前，Biddle先生曾于2013年11月至2015年12月在基因泰克担任眼科销售和营销副总裁，还曾在诺华和葛兰素史克的多个治疗疾病领域担任欧洲和加拿大的多个全球领导职务。比德尔先生以优异的成绩获得了萨斯喀彻温大学的商业学士学位。


Warner Biddle has served as Kyverna Therapeutics, Inc.'s Chief Executive Officer and a member of Kyverna Therapeutics, Inc.'s Board since September 2024. Mr. Biddle previously worked at Kite Pharma, Inc. from August 2020 to September 2024, where he served as Senior Vice President and Global Head of Commercial. Prior to that, Mr. Biddle served as Vice President and Franchise Head for the Breast/Gynecologic and Skin Cancer Franchises at Genentech from January 2018 to August 2020. During his prolific tenure, he led the cross functional strategy and launches for several key commercial and pipeline products while driving significant portfolio growth. Prior to his oncology roles, Mr. Biddle served as Vice President, Sales and Marketing for Ophthalmology at Genentech from November 2013 to December 2015, and also held various global leadership roles in Europe and Canada across multiple therapeutic disease areas at Novartis and GlaxoSmithKline. Mr. Biddle earned a Bachelor's Degree in Commerce with Honors from the University of Saskatchewan.
Warner Weston Biddle自2024年9月起担任首席执行官和董事会成员。Biddle Previoly先生于2020年8月至2024年9月在Kite Pharma，Inc.工作，曾担任高级副总裁兼全球商务主管。在此之前，Biddle先生曾于2018年1月至2020年8月在基因泰克担任副总裁兼乳腺癌/妇科和皮肤癌特许经营的特许经营负责人。在他多产的任期内，他领导了跨职能战略，并为几个关键的商业和管道产品推出了产品，同时推动了产品组合的显着增长。在担任肿瘤学职务之前，Biddle先生曾于2013年11月至2015年12月在基因泰克担任眼科销售和营销副总裁，还曾在诺华和葛兰素史克的多个治疗疾病领域担任欧洲和加拿大的多个全球领导职务。比德尔先生以优异的成绩获得了萨斯喀彻温大学的商业学士学位。
Warner Biddle has served as Kyverna Therapeutics, Inc.'s Chief Executive Officer and a member of Kyverna Therapeutics, Inc.'s Board since September 2024. Mr. Biddle previously worked at Kite Pharma, Inc. from August 2020 to September 2024, where he served as Senior Vice President and Global Head of Commercial. Prior to that, Mr. Biddle served as Vice President and Franchise Head for the Breast/Gynecologic and Skin Cancer Franchises at Genentech from January 2018 to August 2020. During his prolific tenure, he led the cross functional strategy and launches for several key commercial and pipeline products while driving significant portfolio growth. Prior to his oncology roles, Mr. Biddle served as Vice President, Sales and Marketing for Ophthalmology at Genentech from November 2013 to December 2015, and also held various global leadership roles in Europe and Canada across multiple therapeutic disease areas at Novartis and GlaxoSmithKline. Mr. Biddle earned a Bachelor's Degree in Commerce with Honors from the University of Saskatchewan.
Naji H. Gehchan

Naji H. Gehchan自2025年1月起担任Kyverna Therapeutics，Inc.首席医疗和发展官。Gehchan博士是一位成就卓著的生物制药医师-执行官，在药物开发、商业化和一般管理方面拥有丰富的经验。最近，Gehchan博士于2021年4月至2025年1月在礼来（NYSE：LLY）担任imlunestrant临床开发肿瘤学负责人。在这个角色中，他建立并领导了高绩效团队，以敏捷和速度推进礼来的下一代口腔SERD从第1阶段到全球提交。Gehchan博士于2008年10月加入礼来，担任跨地区和跨职能的各种领导职务。2019年9月至2021年4月，他在美国糖尿病领导团队担任销售副总裁。此前，他曾于2015年8月至2019年9月担任BioMedicines首席营销官兼业务部门负责人，领导在法国和其他欧洲国家推出礼来的免疫学产品组合。在加入礼来之前，他曾于2008年4月至2008年10月在强生担任医疗顾问、内科医学与健康经济学。Gehchan博士还在2005年6月至2007年6月期间担任Hotel-Dieu de France和CHU Montpellier的主治医师和内科住院医师。除了职业生涯，Gehchan博士自2023年以来一直担任麻省理工学院斯隆学院的教师导师和客座讲师，并自2019年起担任ESCP商学院的领导力和管理讲师。Gehchan博士于2006年获得医学博士学位，2004年获得贝鲁特圣约瑟夫大学生物科学硕士学位（遗传学和免疫学），2009年获得ESCP商学院的医疗保健管理专业硕士学位，2022年获得麻省理工学院斯隆的高级工商管理硕士学位。


Naji H. Gehchan has served as Kyverna Therapeutics, Inc.'s Chief Medical and Development Officer since January 2025. Dr. Gehchan is an accomplished biopharmaceutical physician executive with extensive experience in drug development, commercialization and general management. Most recently, Dr. Gehchan served as Head of Clinical Development Oncology for imlunestrant at Eli Lilly & Co. (NYSE: LLY), from April 2021 to January 2025. In this role, he built and led high performing teams to advance with agility and speed Eli Lilly's next generation oral SERD from Phase 1 to global submission. Dr. Gehchan joined Eli Lilly in October 2008, holding various leadership roles across geographies and functions. From September 2019 to April 2021, he served as Associate Vice President of Sales on the U.S. Diabetes Leadership Team. Previously, he served as Chief Marketing Officer and Business Unit Head, BioMedicines, from August 2015 to September 2019, leading the launches of Eli Lilly's immunology portfolio across France and other European countries. Prior to joining Eli Lilly, he worked at Johnson & Johnson as a Medical Advisor, Internal Medicine & Health Economics from April 2008 to October 2008. Dr. Gehchan also served as an Attending Physician and Resident in internal medicine at Hotel Dieu de France and CHU Montpellier from June 2005 to June 2007. In addition to his professional career, Dr. Gehchan has been a Faculty Mentor and Guest Lecturer at MIT Sloan since 2023, and a Lecturer in Leadership and Management at ESCP Business School since 2019. Dr. Gehchan earned his Doctor of Medicine in 2006, and Masters in Biological Sciences (Genetics and Immunology) in 2004 from Saint Joseph University of Beirut, a Specialized Masters in Healthcare Management from ESCP Business School in 2009, and an Executive Master of Business Administration from the Massachusetts Institute of Technology Sloan in 2022.
Naji H. Gehchan自2025年1月起担任Kyverna Therapeutics，Inc.首席医疗和发展官。Gehchan博士是一位成就卓著的生物制药医师-执行官，在药物开发、商业化和一般管理方面拥有丰富的经验。最近，Gehchan博士于2021年4月至2025年1月在礼来（NYSE：LLY）担任imlunestrant临床开发肿瘤学负责人。在这个角色中，他建立并领导了高绩效团队，以敏捷和速度推进礼来的下一代口腔SERD从第1阶段到全球提交。Gehchan博士于2008年10月加入礼来，担任跨地区和跨职能的各种领导职务。2019年9月至2021年4月，他在美国糖尿病领导团队担任销售副总裁。此前，他曾于2015年8月至2019年9月担任BioMedicines首席营销官兼业务部门负责人，领导在法国和其他欧洲国家推出礼来的免疫学产品组合。在加入礼来之前，他曾于2008年4月至2008年10月在强生担任医疗顾问、内科医学与健康经济学。Gehchan博士还在2005年6月至2007年6月期间担任Hotel-Dieu de France和CHU Montpellier的主治医师和内科住院医师。除了职业生涯，Gehchan博士自2023年以来一直担任麻省理工学院斯隆学院的教师导师和客座讲师，并自2019年起担任ESCP商学院的领导力和管理讲师。Gehchan博士于2006年获得医学博士学位，2004年获得贝鲁特圣约瑟夫大学生物科学硕士学位（遗传学和免疫学），2009年获得ESCP商学院的医疗保健管理专业硕士学位，2022年获得麻省理工学院斯隆的高级工商管理硕士学位。
Naji H. Gehchan has served as Kyverna Therapeutics, Inc.'s Chief Medical and Development Officer since January 2025. Dr. Gehchan is an accomplished biopharmaceutical physician executive with extensive experience in drug development, commercialization and general management. Most recently, Dr. Gehchan served as Head of Clinical Development Oncology for imlunestrant at Eli Lilly & Co. (NYSE: LLY), from April 2021 to January 2025. In this role, he built and led high performing teams to advance with agility and speed Eli Lilly's next generation oral SERD from Phase 1 to global submission. Dr. Gehchan joined Eli Lilly in October 2008, holding various leadership roles across geographies and functions. From September 2019 to April 2021, he served as Associate Vice President of Sales on the U.S. Diabetes Leadership Team. Previously, he served as Chief Marketing Officer and Business Unit Head, BioMedicines, from August 2015 to September 2019, leading the launches of Eli Lilly's immunology portfolio across France and other European countries. Prior to joining Eli Lilly, he worked at Johnson & Johnson as a Medical Advisor, Internal Medicine & Health Economics from April 2008 to October 2008. Dr. Gehchan also served as an Attending Physician and Resident in internal medicine at Hotel Dieu de France and CHU Montpellier from June 2005 to June 2007. In addition to his professional career, Dr. Gehchan has been a Faculty Mentor and Guest Lecturer at MIT Sloan since 2023, and a Lecturer in Leadership and Management at ESCP Business School since 2019. Dr. Gehchan earned his Doctor of Medicine in 2006, and Masters in Biological Sciences (Genetics and Immunology) in 2004 from Saint Joseph University of Beirut, a Specialized Masters in Healthcare Management from ESCP Business School in 2009, and an Executive Master of Business Administration from the Massachusetts Institute of Technology Sloan in 2022.
Mayo Pujols

Mayo Pujols最近，Pujols先生担任Castle Creek生物科学公司的首席运营官，负责监督晚期自体细胞疗法运营。在加入Castle Creek之前，Pujols先生曾在Rocket制药担任CTO，在那里他指导多个基因治疗项目通过了关键的监管里程碑。他还曾担任合同开发和制造公司Andelyn Biosciences的首席执行官，在那里他建立并扩展了biness，为细胞和基因治疗公司提供服务。在其职业生涯的早期，Pujols先生曾担任多个全球技术运营职位，包括在诺华担任细胞和基因治疗全球主管，在Celgene as ll担任全球CAR T运营和技术副总裁，在Advaxis、默沙东、阿斯利康/MedImmune和Schering Plough.Mr.担任高级职务。Pujols拥有哥伦比亚大学化学工程学硕士学位和史蒂文斯理工学院化学工程学学士学位。


Mayo Pujols has served as Kyverna Therapeutics, Inc.'s Chief Technology Officer since February 2026. Prior to joining Kyverna, Mr. Pujols served as Chief Operating Officer of Castle Creek Biosciences, Inc., a late stage company developing re dosable gene therapies, from June 2025 to January 2026. Prior to that, Mr. Pujols served as Executive Vice President and Chief Technology Officer at Rocket Pharmaceuticals, Inc. from July 2022 to June 2025. Prior to joining Rocket in July 2022, Mr. Pujols was Chief Executive Officer of Andelyn Biosciences Inc. ("Andelyn"), a biopharmaceutical contract development and manufacturing organization ("CDMO"), from June 2020 through July 2022, where he led their expansion to a full service gene therapy CDMO. Prior to his time at Andelyn, Mr. Pujols served as Vice President, Head of Global Cell and Gene Technical Development and Manufacturing at Novartis, a multinational pharmaceutical corporation, from July 2018 through June 2020. Prior to Novartis, Mr. Pujols was the Vice President of Global CAR T Operations and Technology at Celgene, a pharmaceutical company, from August 2017 through July 2018. Earlier in his career, he also held key roles at Merck, Advaxis, MedImmune and Schering Plough. Mr. Pujols earned his bachelor's degree in Chemical Engineering from Stevens Institute of Technology and his master's in Chemical Engineering and Applied Chemistry from Columbia University's The Fu Foundation School of Engineering and Applied Science.
Mayo Pujols最近，Pujols先生担任Castle Creek生物科学公司的首席运营官，负责监督晚期自体细胞疗法运营。在加入Castle Creek之前，Pujols先生曾在Rocket制药担任CTO，在那里他指导多个基因治疗项目通过了关键的监管里程碑。他还曾担任合同开发和制造公司Andelyn Biosciences的首席执行官，在那里他建立并扩展了biness，为细胞和基因治疗公司提供服务。在其职业生涯的早期，Pujols先生曾担任多个全球技术运营职位，包括在诺华担任细胞和基因治疗全球主管，在Celgene as ll担任全球CAR T运营和技术副总裁，在Advaxis、默沙东、阿斯利康/MedImmune和Schering Plough.Mr.担任高级职务。Pujols拥有哥伦比亚大学化学工程学硕士学位和史蒂文斯理工学院化学工程学学士学位。
Mayo Pujols has served as Kyverna Therapeutics, Inc.'s Chief Technology Officer since February 2026. Prior to joining Kyverna, Mr. Pujols served as Chief Operating Officer of Castle Creek Biosciences, Inc., a late stage company developing re dosable gene therapies, from June 2025 to January 2026. Prior to that, Mr. Pujols served as Executive Vice President and Chief Technology Officer at Rocket Pharmaceuticals, Inc. from July 2022 to June 2025. Prior to joining Rocket in July 2022, Mr. Pujols was Chief Executive Officer of Andelyn Biosciences Inc. ("Andelyn"), a biopharmaceutical contract development and manufacturing organization ("CDMO"), from June 2020 through July 2022, where he led their expansion to a full service gene therapy CDMO. Prior to his time at Andelyn, Mr. Pujols served as Vice President, Head of Global Cell and Gene Technical Development and Manufacturing at Novartis, a multinational pharmaceutical corporation, from July 2018 through June 2020. Prior to Novartis, Mr. Pujols was the Vice President of Global CAR T Operations and Technology at Celgene, a pharmaceutical company, from August 2017 through July 2018. Earlier in his career, he also held key roles at Merck, Advaxis, MedImmune and Schering Plough. Mr. Pujols earned his bachelor's degree in Chemical Engineering from Stevens Institute of Technology and his master's in Chemical Engineering and Applied Chemistry from Columbia University's The Fu Foundation School of Engineering and Applied Science.